On this page
Signal check
What changed—and what was not tested
The conjugated derivatives showed antiaggregation activity under conditions where the parent peptides did not show the same pattern. A modified-peptide result cannot be assigned to ordinary Semax or used as a blood-thinner recommendation.
[Antiaggregation activity of arachidonic acid conjugates with neurotropic peptides proglyprol and semax]. (2014)
- Measured signal
- Aggregation responses to the modified peptides and parent compounds.
- Design
- In-vitro platelet-aggregation comparison involving arachidonic-acid conjugates.
- Population or preparation
- Laboratory platelet preparations challenged with aggregation triggers.
- Reported change
- The conjugated derivatives showed antiaggregation activity under conditions where the parent peptides did not show the same pattern.
- Inference boundary
- A modified-peptide result cannot be assigned to ordinary Semax or used as a blood-thinner recommendation.
The experimental design
In-vitro platelet-aggregation comparison involving arachidonic-acid conjugates.
Who or what was studied
Laboratory platelet preparations challenged with aggregation triggers.
The measurement
Aggregation responses to the modified peptides and parent compounds. For a separate account of anticoagulant, fibrinolytic and platelet-related measurements, read Semax and coagulation in stressed rats. For a separate account of enzyme inhibition by semax, selank and peptide fragments, read Semax and serum peptidases.
The reported finding
The conjugated derivatives showed antiaggregation activity under conditions where the parent peptides did not show the same pattern. The added residue is not an inert detail. Chemical conjugation can alter exposure, interaction and behavior, so a name containing Semax does not establish equivalence to the peptide sold in a nasal preparation.
What the result cannot establish
A modified-peptide result cannot be assigned to ordinary Semax or used as a blood-thinner recommendation. Ask for the complete molecular identity before interpreting an alleged upgrade or stronger version. More favorable laboratory activity in one assay does not demonstrate a safer or more useful medicine. The consultation checklist can help you ask which part of this experimental result matches the preparation and goal under discussion.
A related comparison
Our N-acetyl Semax and copper guide makes a related identity distinction using another modification and a different measurement. Neither study is a head-to-head clinical product trial.
Evidence index
Original research and documented service details.